NextCure

$11.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-1.73%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NextCure and other stocks, options, and ETFs commission-free!

About NXTC

NextCure, Inc. Common Stock, also called NextCure, is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. The listed name for NXTC is NextCure, Inc. Common Stock.

CEO
Michael S. Richman
Employees
69
Headquarters
Beltsville, Maryland
Founded
2015
Market Cap
306.78M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
200.76K
High Today
$11.75
Low Today
$11.00
Open Price
$11.72
Volume
176.66K
52 Week High
$45.15
52 Week Low
$7.91

NXTC Earnings

-$0.61
-$0.30
$0.02
$0.33
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

DTH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure